Foundations acquire a critical new role as federal funding for cancer research falters

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The fight against cancer is complex. It’s global. And it’s indisputably expensive. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Association for Cancer Research-Novocure Career Development Award for Cancer Research represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field. 
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login